drugset / Trial / NCT06966362

Varenicline for Smoking Reduction in Veterans Not Ready To Quit

NCT06966362

Phase 4 Not yet recruiting 400 enrolled VA Office of Research and Development
RandomizedParallel-groupSingle-blindTreatment

Summary

In order to reduce the prevalence of cigarette smoking among Veterans, it is vital that healthcare providers offer effective tobacco treatment to all Veterans who smoke, including those not ready to make a quit attempt. Smoking treatments currently available to Veterans who are not ready to quit are only weakly effective. This project will generate new knowledge about the effectiveness of a promising varenicline-based intervention designed to increase quit attempts and long-term abstinence in Veterans who are initially not ready to quit. This project has great potential to engage Veterans not ready to quit smoking in treatment that increases quit attempts and quitting success, thereby reducing morbidity and mortality caused by smoking in Veterans.

Timeline

Start
2026-07-20
Primary completion
2030-06-28
Completion
2030-06-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nicotine Unknown 2 mg
Comparator Nicotine Unknown 4 mg
Comparator Nicotine Unknown 7 mg
Comparator Nicotine Unknown 14 mg
Comparator Nicotine Unknown 21 mg
Subject Varenicline Small molecule 1 mg

Indications